{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'at Day 15 (Visit 4) will be analyzed for the FAS using an ANCOVA model adjusting for study', 'drug group, site, and baseline PRQLQ (linear, continuous covariate).', 'Further detail on the analyses of all efficacy endpoints including tertiary endpoints will be', 'detailed in the SAP.', '13.7.3.', 'Hierarchical Testing', 'Treatment comparisons will begin with the primary endpoint versus placebo. If the resulting', 'two-sided p-value is less than 0.05, then the next comparison of the secondary endpoint will be', 'made, in the order of clinical importance, as outlined below. This process continues until either', 'all comparisons of interest are made, or until the point at which the resulting two-sided p-value', 'for a comparison of interest is greater than 0.05.', 'In order to control the type I error for multiple endpoints, the testing of the secondary endpoints', 'will be performed sequentially in the following order, at the end of the 14 days treatment period:', 'Change from baseline in average AM and PM subject-reported 12-hour instantaneous', 'Total Nasal Symptom Score (iTNSS) over the 14-day treatment period.', 'Change from baseline in the overall Pediatric Rhinoconjunctivitis Quality of Life', 'Questionnaire (PRQLQ) score on Day 15 (Visit 4) between treatment groups.', 'Change from baseline in average AM and PM subject-reported 12-hour reflective', 'Total Ocular Symptom Score (rTOSS) over the 14-day treatment period.', 'Once one of the tests as ordered above is not significant, the testing will no longer be performed', 'for the remainder of the endpoints. No multiplicity adjustments will be made for the \"Other', \"efficacy endpoints'.\", '13.8.', 'Safety Analyses', 'All safety analyses will be performed on the SAS. Unless otherwise specified, \"baseline\\' will be', 'defined as the last available assessment prior to the first dose of study drug following', 'randomization.', '13.8.1.', 'Extent of Exposure', 'The number of subjects exposed to each study drug will be summarized. The number of days on', 'treatment and the number of days on study (placebo run-in plus treatment periods) will be', 'summarized by study drug. In addition, treatment compliance will be summarized by categories', 'to <100%, > 100% to 125%, >125%) and study drug.', '13.8.2.', 'Adverse Events', 'Adverse events will be coded using the current Medical Dictionary for Regulatory Activities', '(version 19 or higher). The number and percentage of AEs, SAEs, AEs leading to', 'discontinuation, and AEs related to the IP will be summarized by system organ class (SOC),', 'preferred term (PT), and treatment group. The number and percentage of AEs by severity will', 'also be summarized. All AEs will be displayed in listings. Any AE that occurs during the', 'placebo run-in period will be summarized separately. A comparison of the incidence rate of AEs', 'between study drug groups will be presented.', 'Glenmark', 'CONFIDENTIAL', 'Page 64 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '13.8.3.', 'Adverse Events, Concomitant Medications, and Withdrawals', 'All AEs will be coded according to the current version of Medical Dictionary for Regulatory', 'Activities, version 19 or higher. Adverse events occurring between the signing of informed', 'consent and administration of the first dose (randomized treatment) of study medication will be', 'regarded as pre-treatment AEs and included in the subject listings but not in the summary tables.', 'Adverse events occurring after the first dose of study medication will be defined as TEAEs and', 'will be listed and summarized by SOC and PT.', 'Summaries of the number of subjects with TEAEs and the number of TEAEs experienced will be', 'presented by treatment. The number of subjects and the number of TEAEs will be presented', 'using frequency counts and percentages, overall and by SOC and PT. Tables of the number and', 'percentage of subjects and the number of TEAEs by intensity and by relationship to study', 'medication will also be presented. Events will be assigned to the study drug administered prior', 'to the start of the TEAE. Events that occurred during the study discontinuation visit and final', 'follow-up will be assigned to the final treatment.', 'Details of SAEs and AEs leading to withdrawal of the subject from the study will also be', 'presented by treatment group. Withdrawals from the study, and associated details, will be', 'presented by treatment group. Any withdrawals will be listed and summarized by reason for', 'withdrawal, treatment and by any other relevant categorical information.', 'Concomitant medications will be listed.', '13.8.4.', 'Vital Signs', 'Descriptive statistics will be used to summarize vital sign results and changes from baseline by', 'treatment group and time. Values of potential clinical significance will be defined in the SAP.', 'The number of subjects with values of potential clinical significance will be tabulated. All vital', 'signs data will be displayed in listings.', '13.8.5.', 'Physical Examinations', 'Descriptive statistics will be used to summarize physical examination results and changes from', 'baseline by treatment group and time. The number of subjects with findings of potential clinical', 'significance will be tabulated. All physical examination data will be displayed in listings.', '13.8.6.', 'Focused Ears, Nose, and Throat (ENT)/Eye Examinations', 'Descriptive statistics will be used to summarize ENT/eye results and changes from baseline by', 'treatment group and time. The number of subjects with findings of potential clinical significance', 'will be tabulated. All ENT/eye data will be displayed in listings.', '13.9.', 'Interim Analysis', 'No interim analysis is planned for this study.', 'Glenmark', 'CONFIDENTIAL', 'Page 65 of 90']\n\n###\n\n", "completion": "END"}